Region-specific and dose-specific effects of chronic haloperidol exposure on $[^3]$HFlumazenil and $[^3]$HRo15-4513 GABA$_A$ receptor binding sites in the rat brain

Alba Peris-Yague$^{1,5}$, MSc; Amanda Kiemes$^2$, MSc; Diana Cash$^1$, PhD; Marie-Caroline Cotel$^3$, PhD; Nisha Singh$^{1,6}$, PhD; Anthony C. Vernon$^{*3,4}$, PhD and Gemma Modinos$^{*1,2,4}$, PhD.

$^1$Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, London SE5 8AF, United Kingdom
$^2$Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, London SE5 8AF, United Kingdom
$^3$Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road, London SE5 9RT, United Kingdom
$^4$MRC Centre for Neurodevelopmental Disorders, King’s College London, London, United Kingdom
$^5$Current address: Laboratory for Clinical Neuroscience, CTB, Universidad Politécnica de Madrid, Madrid, Spain
$^6$Current address: Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX

*Joint senior authors

Correspondence should be addressed to either:

Dr Gemma Modinos
Department of Psychosis Studies
Institute of Psychiatry, Psychology and Neuroscience,
King’s College London
16 De Crespigny Park
London SE5 8AF
United Kingdom
Tel: +44(0)2078480927
Email: gemma.modinos@kcl.ac.uk

Dr Anthony C. Vernon
Department of Basic and Clinical Neuroscience,
Institute of Psychiatry, Psychology and Neuroscience,
King’s College London
Maurice Wohl Clinical Neuroscience Institute
5 Cutcombe Road
London SE5 9RT
United Kingdom
Tel: +44 (0) 207 848 5311
Email: anthony.vernon@kcl.ac.uk
Abstract

Data from post-mortem studies suggest that schizophrenia is associated with abnormal expression of GABA\(_A\) receptor (GABA\(_A\)R) \(\alpha\) subunits including \(\alpha5\)GABA\(_A\). Positron emission tomography (PET) measures of GABA\(_A\)R binding in schizophrenic patients, however, have not revealed consistent alterations in vivo. Animal studies using the GABA\(_A\)R agonist \[^3\text{H}]\text{muscimol}\) have provided evidence that antipsychotic drugs used in schizophrenia can influence GABA\(_A\)R binding, in a region-specific manner, complicating the interpretation of the PET GABA signal in medicated patients. No binding data, however, are available for more subunit-selective ligands. To address this, we combined a rodent model of clinically relevant antipsychotic drug exposure with quantitative receptor autoradiography. Haloperidol (0.5 and 2 mg/kg/day) or vehicle were continuously administered to adult male Sprague-Dawley rats via osmotic pumps to maintain a clinically relevant, steady-state levels of drug exposure for 28 days. Quantitative receptor autoradiography was then performed post-mortem using the GABA\(_A\) selective radioligand \[^3\text{H}]\text{Ro15-4513}\) and the non-subunit selective radioligand \[^3\text{H}]\text{flumazenil}\). Chronic haloperidol exposure increased \[^3\text{H}]\text{Ro15-4513}\) binding in the CA1 sub-field of the dorsal hippocampus (\(p<0.01; \text{q}<0.01\)). \[^3\text{H}]\text{flumazenil}\) binding was also increased in most of the explored regions (\(p<0.05\)), independently of the dose of haloperidol used. This is the first study to demonstrate a region/dose-specific effect of haloperidol on \[^3\text{H}]\text{Ro15-4513}\) binding. Although caution needs to be exerted when extrapolating results from animals to patients, collectively these data confirm previous findings that antipsychotic treatment contributes to the heterogeneity observed in PET studies of GABA\(_A\)R in schizophrenic patients, specifically at the \(\alpha1/5\)GABA\(_A\)R.
Introduction

γ-Amino-butyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (CNS). The GABA\(_A\) receptor (GABA\(_A\)R) is a pentameric GABA-gated chloride ion channel composed of several classes of subunits (α1–6, β1–3, γ1–3, δ, θ, ρ, and ε) [1]. Of these, the diversity of the α-subunit is thought to be responsible for shaping the functional properties and ligand selectivity of the GABA\(_A\) benzodiazepine binding site (GABA\(_A\)-BZR) [2–5]. Benzodiazepines act at the α/γ interface for the α subunits 1, 3, 5 [6]. In the CNS, GABA\(_A\)-BZR mediate pyramidal cell activity via tonic and phasic inhibition [7–9].

Deficits in GABA neurotransmission, resulting in disruptions to normal patterns of neural oscillatory activity are implicated in the pathophysiology of schizophrenia [10–13]. In support of this, quantitative receptor autoradiography studies using \(^3\)Hmuscimol, an orthosteric agonist at the GABA binding site on GABA\(_A\)-BZR, provide consistent evidence for increased binding density in frontal and temporal cortices and the caudate nucleus in post-mortem brain tissue from patients with schizophrenia [14–19].

In contrast, post-mortem studies focusing specifically on mRNA expression of GABA\(_A\) α-subunits report decreased expression of α1 [20,21], increased expression of α2 [21,22], but inconsistent results for the α5-subunit [21,23,24]. A systematic review of positron emission tomography (PET) studies in schizophrenia patients using selective radiotracers for the BZ-site of the GABA\(_A\)-BZR however found no consistent evidence for altered GABA\(_A\)-BZR availability in schizophrenia [25].

These post-mortem data come from patients with a long duration of illness and exposure to antipsychotic medication. Similarly in most of the PET studies, the patients were also receiving antipsychotic medication [25], and it has been shown that different
antipsychotics can directly alter the binding of ligands to GABA<sub>A</sub>-BZR, presumably by altering the expression and availability of the receptors [26,27]. Hence, distinguishing effect(s) of illness from antipsychotic exposure is challenging and medication may represent a significant source of heterogeneity in these data.

In support of this view, pre-clinical studies in naïve adult rats show that chronic exposure to antipsychotic haloperidol directly influences binding of both [³H]muscimol (indexing GABA<sub>A</sub>R binding) and [³H]flunitrazepam (indexing BZ-site binding) in a duration of exposure and region-dependent manner [28–35]. These studies however have not been able to fully unravel this complex issue completely. While exposure of adolescent rats to antipsychotic drugs has recently been reported to increase [³H]muscimol binding in the striatum and nucleus accumbens [36] a 12-day exposure to haloperidol is reported to decrease [³H]flumazenil binding in several regions of the naïve rat brain [34]. Collectively, these data strongly suggest that exposure to antipsychotic medication influences GABA<sub>A</sub>-BZR availability in vivo, but the direction of this effect remains ambiguous. Notably, these studies investigating effects of D<sub>2</sub> dopaminergic receptor (D2R)-based antipsychotics on GABA<sub>A</sub>-BZR involved routes of administration that result in inappropriate pharmacokinetics that does not match a clinically comparable exposure [23].

The binding sites to the GABA<sub>A</sub>-BZR allosteric ligand, [³H]flumazenil, in the rodent and human brain have been shown to comprise both the “zolpidem-sensitive” and “zolpidem-insensitive sites”, with the latter suggested to correspond to GABA<sub>A</sub>Rs that contain the α5 subunit [38]. In a recent study, 12 days of systemic haloperidol exposure resulted in a significant reduction in zolpidem-sensitive binding sites (α1,2,3GABA<sub>A</sub>R [39]), with no effect on the insensitive-binding sites, suggesting a lack of effect on α5GABA<sub>A</sub>Rs.
No studies however, have examined the potential impact of antipsychotic drug exposure using radioligands with greater selectivity for GABA<sub>A</sub>-BZR containing α1/α5 subunits, such as Ro15-4513 [40,41]. This is relevant, since convergent lines of evidence from animal models strongly suggest that α5GABA<sub>A</sub>R have potential as a target for novel, non-dopaminergic antipsychotic compounds, by balancing hippocampal excitation via tonic inhibition of pyramidal neurons [42–49]. Notably, the efficacy of the compound SH-053-2F-R-CH3, an α5GABA<sub>A</sub>R positive allosteric modulator (PAM), in the methylazoxymethanol acetate (MAM) neurodevelopmental disruption model of schizophrenia is compromised following prior exposure to the D2R antagonist haloperidol [41].

In the present study we therefore aimed to determine the impact of chronic exposure to haloperidol on GABA<sub>A</sub>R binding using post-mortem quantitative receptor autoradiography with [3H]Ro15-4513 to assess α1/α5GABA<sub>A</sub>R and [3H]flumazenil to assess BZ-sensitive α1-3;5GABA<sub>A</sub>R using a validated rat model of clinically comparable drug exposure [37,50]. Based on the results of McLeod and colleagues (2008) who observed decreases in zolpidem-sensitive binding sites and no change in zolpidem-insensitive sites after haloperidol exposure, we hypothesized that chronic haloperidol exposure would decrease [3H]flumazenil binding, with no effect on [3H]Ro15-4513 binding.

**Methods**

**Animals and treatment protocol**

Male Sprague-Dawley rats (N=36, Charles River, UK; ~ 10 weeks of age) were administered haloperidol (0.5 or 2 mg/kg/day; haloperidol; n=12/group: Sigma-Aldrich,
Gillingham, Dorset, UK) or vehicle (β-hydroxypropylcycloDEXtrin, 20% w/v, acidified to pH 6 using ascorbic acid; n=12/group) using osmotic minipumps for 28 days [31]. Dyskinetic behavior, i.e., vacuous chewing movements, was assessed once at 26 days after the start of haloperidol exposure. This involved a simple measurement of purposeless chewing jaw movements in a 2-minute period, outside the home cage as described previously [50]. All experimental procedures were performed in accordance with the relevant guidelines and regulations, specifically, the Home Office (Scientific Procedures) Act 1986, United Kingdom and European Union (EU) directive 2010/63/EU and the approval of the local Animal Welfare and Ethical Review Body (AWERB) panels at King’s College London (for full details, see supplementary material).

Quantitative receptor autoradiography with \[^{3}H\]Ro15-4513 and \[^{3}H\]flumazenil

On completion of treatment, rats were terminally anesthetized and perfused. A plasma sample was collected for estimation of drug levels. Coronal 20 μm-thick sections were cut using a cryostat (Leica CM1950), mounted onto glass slides (Superfrost\textsuperscript{TM}) and stored at -80°C until used for autoradiography (for further details, see supplementary material).

\[^{3}H\]Ro15-4513 (Perkin Elmer, NET925250UC) was used to quantify α1/5GABA\textsubscript{AR} density. While this ligand has a high specificity (60-70%) [51] to α5GABA\textsubscript{AR}, a smaller proportion of the binding has affinity to α1GABA\textsubscript{AR} [52]. Non-specific binding was determined by bretazenil (Sigma, B6434-25MG) due to its affinity to bind to a variety of GABA\textsubscript{AR} subtypes (α1-3;5) [53]. Sections were pre-incubated at room temperature in Tris buffer (50 mM) for 20 minutes followed by incubation in either 2 nM \[^{3}H\]Ro15-4513 for specific binding, or 2 nM of \[^{3}H\]Ro15-4513 and 10 μM of bretazenil for non-specific binding at room temperature for 60 minutes. Slides were then washed in Tris buffer (2 x 2 min) at room temperature, dipped in distilled water (dH\textsubscript{2}O) and left to dry.
overnight. Dry slides were placed into light-tight cassettes with a radioactive \[^3\text{H}\] standards slide, (ART-123A American Radiolabelled Chemicals Inc., USA) and hyperfilm (Amersham 8x10 in Hyperfilm Scientific Laboratory Supplies, UK). Films were exposed for 8 weeks before being developed in a Protex Ecomax film developer (Protec GmbH & Co, Germany). Identical procedures were used for \[^3\text{H}\] flumazenil (Perkin Elmer, NET757001MC), with the exception that the slides were incubated and washed in buffer at 4°C with 1nM \[^3\text{H}\] flumazenil, and 10 \(\mu\)M flunitrazepam (Sigma Aldrich, F-907 1ML) and 1nM \[^3\text{H}\] flumazenil, for specific and non-specific binding, respectively, and exposed for 4 weeks before development.

**Quantification of receptor binding**

Films were developed and images were manually captured using a Nikon SLR camera and preprocessed (see supplementary material). Optical density (OD) measurements were obtained using MCID software (Imaging Research Inc., 2003) from \textit{a priori} defined regions of interest (ROIs; Fig. 1). These were chosen based on the known distribution of \(\alpha_1/\alpha_5\text{GABA}_\text{A}R\) in the rat brain, data from prior studies reporting an effect of haloperidol on \[^3\text{H}\] muscimol or \[^3\text{H}\] flunitrazepam binding [31–34], and a defined role in the pathophysiology of schizophrenia [31,48,54–58]. Specific binding in nCi/mg was quantified using standard curves constructed from OD measurements of standards for each film, using the robust linear regression interpolation method in GraphPad (version 8.00, GraphPad Software, La Jolla California USA [www.graphpad.com]).
**Figure 1.** Representative $[^3]H$Ro15-4513 autoradiographs showing the placement of ROIs that were analyzed in this study. The same ROIs were used for the analysis of $[^3]H$flumazenil. A) dorsal hippocampal layers CA1 (dCA1), CA2 (dCA2), CA3 (dCA3), dentate gyrus (DG) and amygdala (amy). B) ventral hippocampal layers CA1 (vCA1), CA3 (vCA3). C) Medial Prefrontal Cortex (upper (1-3) and deeper (4-6) mPFC), Anterior Cingulate Cortex (upper (1-3) and deeper (4-6) ACC), differentiation of upper (1-3) vs deeper (4-6) layers was due to differential density of receptors across layers, specifically with $\alpha_5$ being more predominantly present in layer V and VI [59]. D) Caudate-Putamen (CPu), Nucleus Accumbens (NAc).

**Statistical Analyses**

All statistical analyses were performed in Prism software (v8.0.0 for Macintosh, GraphPad Software, La Jolla California USA, [www.graphpad.com](http://www.graphpad.com)). The data were initially checked for significant outliers using Grubbs’ test ($\alpha=0.05$) with any significant outliers excluded from the final analysis. The data were then checked for Gaussian
distribution using the Shapiro-Wilk normality test. Autoradiographic data were normally distributed (Shapiro-Wilk, $p>0.05$), but vacuous chewing movements scores were not (Shapiro-Wilk, $p<0.01$). Group-level differences in ligand binding were assessed using mixed-effects model, with ROI as within-subject factor and treatment (vehicle, haloperidol 0.5 or 2 mg/kg/day) as between-subject factor, using the specific binding (nCi/mg) of either $[^{3}H]$Ro15-4513 or $[^{3}H]$flumazenil as the dependent variable. Vacuous chewing movements scores were analyzed using non-parametric Kruskal-Wallis test ($p<0.001$). Post-hoc tests were performed where appropriate and corrected for multiple comparisons using the 2-stage set-up method of Benjamini, Krieger and Yekutieli, with the false discovery rate set at 5% ($q<0.05$) [60]. Relationships between vacuous chewing movements and ligand binding were modeled using non-parametric Spearman’s Rho correlation (2-tailed).

Results

Haloperidol plasma levels and vacuous chewing movement behavior

Administration of haloperidol by osmotic pump achieved plasma levels (mean ± s.d.) of $2.96 \pm 0.52$ ng/mL and $12.2 \pm 1.96$ ng/mL, for dose haloperidol 0.5 and 2 mg/kg/day, respectively. Stereotypical vacuous chewing movement behaviors were significantly different across treatment group (Kruskal-Wallis statistic = 9.98; $p<0.001$; Fig. S1). Post-hoc testing revealed a significant increase in vacuous chewing movements in those animals exposed to 2 mg/kg/day haloperidol after 26 days exposure, as compared to vehicle ($p<0.01$; $q<0.05$). There were no statistically significant differences between the haloperidol-exposed groups ($p>0.05$; $q>0.05$). Vacuous chewing movements were not related to the binding of either $[^{3}H]$Ro15-4513 (Table S1) or $[^{3}H]$flumazenil across any ROI (Table S2). Haloperidol plasma levels did not significantly correlate with binding of either of the ligands used (Table S3).
Dose-specific changes in \[^3\text{H}\]Ro15-4513 binding after haloperidol exposure measured with quantitative autoradiography

Mixed-effects model ANOVA revealed a statistically significant main effect of ROI (F(4,96)=106.2; p<0.0001) and a significant treatment*ROI interaction (F(24, 294)=1.71; p=0.02), but no statistically significant main effect of treatment (F(2, 28)=1.27; p=0.30). Post-hoc testing on the ROI*treatment interaction revealed a statistically significant increase in \[^3\text{H}\]Ro15-4513 specific binding in the dCA1 of rats exposed to 0.5 mg/kg/day haloperidol, as compared to rats exposed to vehicle (p<0.01; q<0.01; Cohen’s $d=1.3$) or 2 mg/kg/day haloperidol (p<0.05; q<0.01; Cohen’s $d=-1.2$) (Table 1; Figure 2). There were no statistically significant differences between 2 mg/kg/day haloperidol exposed rats vs. vehicle (p=0.94; q>0.05). In addition, in the NAc, exposure to 2mg/kg/day haloperidol decreased \[^3\text{H}\]Ro15-4513 binding relative to 0.5mg/kg/day haloperidol-exposed rats (p<0.001; q<0.001), although this did not reach statistical significance with respect to vehicle controls (vehicle vs 0.5mg/kg/day: p=0.07; q=0.049; vehicle vs. 2mg/kg/day: p=0.06, q=0.049) (Table 1; Figure 2). All other ROIs showed no statistically significant changes in \[^3\text{H}\]Ro15-4513 binding after 28 days exposure to haloperidol, irrespective of the dose.
Table 1. Regional binding (nCi/mg) of $[^3]$HRO15-4513 across the ROIs explored, data show mean (SD, N). Prefrontal Cortex (PFC), Anterior Cingulate Cortex (ACC), upper layer (1-3) and deeper layer (4-6); Caudate-Putamen (CPu), Nucleus Accumbens (Nac); dorsal hippocampal layers CA1 (dCA1), CA2 (dCA2), CA3 (dCA3), dentate gyrus (DG); ventral hippocampal layers CA1 (vCA1), CA3 (vCA3); amygdala (Amy).

*Vehicle vs. Haloperidol 0.5 mg/kg/day (q<0.01), # Haloperidol 0.5 mg/kg/day vs. Haloperidol 2 mg/kg/day (q<0.01), ## (q<0.001)

| ROI                      | Vehicle     | HAL 0.5mg/kg/day | HAL 2mg/kg/day | Veh vs. HAL 0.5mg/kg/day | Veh vs. HAL 2mg/kg/day | HALO.5mg/kg/day vs. HAL12mg/kg/day |
|--------------------------|-------------|------------------|----------------|--------------------------|------------------------|----------------------------------|
| Upper layer mPFC         | 2.78 (1.28, 8) | 2.52 (1.06, 11) | 1.97 (1.26, 9) | p=0.64; q=0.68           | p=0.37; q=0.50        | p=0.42; q=0.66                   |
| Deeper layer mPFC        | 5.99 (2.06, 9) | 5.69 (1.38, 12) | 5.22 (1.34, 10)| p=0.71; q=0.75           | p=0.35; q=0.66        | p=0.42; q=0.66                   |
| Upper layer ACC          | 2.37 (1.02, 8) | 2.31 (0.73, 11) | 1.76 (1.08, 8) | p=0.90; q=0.94           | p=0.27; q=0.42        | p=0.24; q=0.42                   |
| Deeper layer ACC         | 4.85 (1.31, 9) | 4.66 (1.07, 12) | 4.61 (1.03, 10)| p=0.72; q=0.96           | p=0.66; q=0.92        | p=0.92; q=0.96                   |
| CPu                      | 0.44 (0.34, 5) | 0.46 (0.40, 8)  | 0.48 (0.39, 4) | p=0.94; q=0.99           | p=0.90; q=0.99        | p=0.95; q=0.99                   |
| NAc                      | 1.54 (0.77, 7) | 2.30 (0.76, 9)  | 0.80 (0.53, 7) | p=0.07; q=0.049          | p=0.06; q=0.049       | p=0.001; q=0.001                 |
| dCA1                     | 6.62 (1.05, 9) | 7.99 (1.09, 12) | 6.66 (1.19, 10) | p<0.01; q<0.01           | p<0.01; q<0.01        | p<0.01; q<0.01                   |
| dCA2                     | 4.45 (1.52, 9) | 4.56 (0.96, 12) | 3.72 (1.36, 10)| p=0.86; q=0.90           | p=0.29; q=0.45        | p<0.12; q<0.38                   |
| DG                       | 3.26 (1.19, 9) | 3.44 (0.86, 12) | 3.13 (0.95, 10)| p=0.71; q=0.84           | p=0.80; q=0.84        | p=0.45; q=0.84                   |
| dCA3                     | 2.44 (0.83, 9) | 3.01 (0.85, 12) | 2.49 (0.86, 10)| p=0.14; q=0.27           | p<0.90; q<0.94        | p=0.17; q=0.27                   |
| vCA1                     | 4.85 (1.26, 3) | 3.71 (1.20, 12) | 2.94 (0.83, 9) | p=0.46; q=0.48           | p=0.26; q=0.41        | p=0.10; q=0.31                   |
| vCA3                     | 3.68 (3.12, 4) | 3.35 (1.65, 12) | 3.98 (1.02, 9) | p=0.85; q=0.90           | p=0.86; q=0.90        | p=0.29; q=0.90                   |
| Amy                      | 2.11 (0.71, 9) | 1.99 (0.68, 12) | 1.83 (0.79, 10)| p=0.72; q=0.76           | p=0.44; q=0.76        | p=0.61; q=0.76                   |

Figure 2. Chronic haloperidol exposure results in dose-specific changes in $[^3]$HRO15-4513 specific binding relative to vehicle controls in the nucleus accumbens (Nac) and dorsal Cornu Ammonis 1 (dCA1). Data points represent the specific binding values per individual animal (nCi/mg), horizontal line indicates group mean, bars indicate SEM.
General increase in [³H]flumazenil binding after haloperidol exposure measured with quantitative autoradiography

Mixed-effects model ANOVA revealed a significant main effect of ROI (F=(4, 114)=124.2; p<0.0001) (Table S4, Figure S2) and treatment (F(2, 28)=3.86; p=0.03), but no ROI*treatment interaction (F (24, 304)=1.22; p=0.23). Across ROIs, the effect of haloperidol exposure was generally to increase [³H]flumazenil-specific binding (see Table 2 and Figure 3).

| ROI                  | Vehicle  | HAL 0.5mg/kg/day | HAL 2mg/kg/day |
|----------------------|----------|------------------|----------------|
| Upper layer mPFC     | 28.22 (8.2, 7) | 35.43 (9.15, 11) | 34.58 (7.95, 9) |
| Deeper layer mPFC    | 33.81 (7.91, 9) | 40.62 (8.18, 11) | 40.93 (8.37, 9) |
| Upper layer ACC      | 35.41 (3.04, 8) | 39.04 (8.84, 12) | 40.89 (8.39, 9) |
| Deeper layer ACC     | 27.05 (6.48, 9) | 35.95 (7.52, 12) | 35.56 (8.83, 9) |
| CPU                  | 5.81 (2.83, 9)  | 8.62 (3.79, 12)  | 6.86 (2.73, 8)  |
| NAc                  | 10.75 (4.33, 9) | 15.43 (5.83, 12) | 18.99 (5.58, 9) |
| dCA1                 | 30.87 (3.36, 8) | 29.03 (3.89, 10) | 34.54 (4.17, 10) |
| dCA2                 | 15.89 (5.37, 9) | 16.89 (5.27, 11) | 19.54 (4.07, 10) |
| DG                   | 26.57 (5.52, 9) | 29.00 (5.84, 11) | 32.58 (4.24, 10) |
| dCA3                 | 17.25 (5.39, 9) | 18.55 (5.36, 11) | 22.10 (4.21, 10) |
| vCA1                 | 14.81 (4.48, 5) | 19.93 (7.07, 11) | 21.81 (4.11, 9) |
| vCA3                 | 14.24 (8.03, 5) | 18.43 (7.53, 11) | 24.24 (5.29, 9) |
| Amy                  | 27.31 (8.11, 8) | 31.08 (6.61, 11) | 34.68 (8.48, 10) |

Table 2. Regional binding (nCi/mg) of [³H]flumazenil across the ROIs explored, data show mean (SD, N). Prefrontal Cortex (PFC), Anterior Cingulate Cortex (ACC), upper layer (1-3) and deeper layer (4-6); Caudate-Putamen (Cpu), Nucleus Accumbens (Nac); dorsal hippocampal layers CA1 (dCA1), CA2 (dCA2), CA3 (dCA3), dentate gyrus (DG); ventral hippocampal layers CA1 (vCA1), CA3 (vCA3); amygdala (Amy).
Figure 3. Pseudocolored representative autoradiographs showing A) $[^3\text{H}]$Ro15-4513 binding patterns and B) $[^3\text{H}]$flumazenil binding, by group: vehicle, haloperidol 0.5 mg/kg/day (halo 0.5), and haloperidol 2 mg/kg/day (halo 2).

Discussion

To our knowledge, this is the first study to investigate the effects of chronic exposure to haloperidol using clinically comparable dosing on GABA$_A$R binding in a receptor subtype-specific manner using quantitative autoradiography. The main findings are that chronic haloperidol exposure results in a dose-specific increase in $[^3\text{H}]$Ro15-4513 binding in the dCA1 of the hippocampus. Precisely, $[^3\text{H}]$Ro15-4513 binding is increased
in rats exposed to haloperidol 0.5 mg/kg/day compared to rats exposed to vehicle with no effect of 2 mg/kg/day haloperidol. In contrast, chronic exposure to haloperidol generally increased $[^3]H$flumazenil binding in most ROIs irrespective of the dose administered. We found no relationship between these changes in ligand binding and vacuous chewing movements, a proxy measure for haloperidol-induced tardive dyskinesia, or drug plasma levels. These data suggest that chronic exposure to haloperidol has distinct, dose- and region-specific effects on the availability of GABA$\alpha$R with specific sub-unit compositions. The present findings confirm that the dose and duration of exposure to haloperidol (and perhaps other antipsychotics) should be considered when measuring and interpreting GABA$\alpha$R binding availability from schizophrenia patients.

Previous autoradiography studies have reported mixed findings regarding the effects of haloperidol exposure on GABA$\alpha$-BZR binding sites. McLeod and Colleagues (2008) reported an overall decrease in $[^3]H$flumazenil binding across cortical and subcortical regions after a 12-day exposure to 1 mg/kg of haloperidol administered once daily via an intraperitoneal injection [34]. In contrast, using a more clinically relevant mode of administration and longer duration of exposure (28 vs. 12 days), our data suggest chronic haloperidol exposure results in a generalized increase in $[^3]H$flumazenil binding across several brain ROIs. The present findings are in concordance with previous research suggesting that chronic haloperidol exposure is associated with increased GABA$\alpha$-BZR density in cortical areas using $[^3]H$flunitrazepam [32,33]. The discrepancies between our findings and those in McLeod and colleagues (2008) could simply reflect methodological differences, due to the differing modes of drug administration [34]. Notably, intraperitoneal administration of haloperidol does not result in clinic-like steady-state plasma levels or pharmacokinetics [37]. Alternatively, there could be bi-phasic, time-dependent effects of haloperidol exposure on GABA$\alpha$R availability. McLeod and
colleagues (2008) also reported no effect of 12-day haloperidol exposure on zolpidem-insensitive $[^3H]$flumazenil binding, which is suggested to reflect $\alpha_5$GABA$_A$ binding sites [34,38]. Hence, it may be speculated that $[^3H]$Ro15-4513 binding might be affected differently following shorter or longer exposure to haloperidol which should be explored by studying clinically-relevant dosages of antipsychotic medication at different time points.

The use of quantitative autoradiography in the present study provides proof-of-concept evidence that exposure to haloperidol affects GABA$_A$-BZR as well as $\alpha_5$GABA$_AR$ specifically. This technique in pre-clinical research is highly advantageous as it provides better spatial resolution than PET studies and sets a translational framework for conducting clinical research with homologue ligands, which other techniques such as histology do not allow. Collectively, our findings and those of others suggest that haloperidol, a D2R antagonist, likely impacts on GABA neurotransmission within the hippocampal-midbrain loop circuitry, which is critically involved in emotion salience and memory and is dysregulated in schizophrenia [61]. Precisely how these drug-induced changes in GABA$_AR$ binding relate to central GABA neurotransmission however remains unclear. Quantitative autoradiography reflects changes in binding of the ligands to available receptor sites, which may relate to either upregulation or downregulation of neurotransmitter release. For example, an increase in receptor binding could indicate a compensatory effect in the form of a reduction in neurotransmitter levels. An increase in GABA levels does nonetheless also enhance affinity of GABA$_AR$ for BZ-ligands such as flumazenil via a conformational change [62–64]. This is not the case, for BZR inverse agonists such as Ro15-4513, in which increased GABA levels appear to decrease the affinity of GABA$_AR$ for this ligand [65]. Hence, increases in $[^3H]$flumazenil binding
could reflect either increased or decreased GABA levels, whilst decreases in \(^3\)H\text{Ro15-4513} binding likely reflect increases in GABA levels and vice versa. Taken together, our observations of increased \(^3\)H\text{Ro15-4513} binding in the dCA1 following exposure to 0.5 mg/kg/day haloperidol may be interpreted as evidence for increases in membrane \(\alpha_1/5\)-GABA\(\text{AR}\) in response to decreased GABA levels [60]. In the higher-dose haloperidol group, we observed vacuous chewing movements, which in rats, it is an analogue measure to tardive dyskinesia observed in humans and can be an indicator of almost complete D2R blocking occupancy [66], that may be causing differential effects on \(\alpha_1/5\text{GABA}\text{AR}\) than the lower-exposure dosages.

The overall increased \(^3\)H\text{flumazenil} binding could be suggestive of increased GABA release. Notably, \textit{in vitro} slice electrophysiology suggests that D2R mediate GABA release onto pyramidal neurons in the PFC, whereby GABA release is decreased following dopamine administration [67]. D2R antagonists, such as haloperidol, would be predicted to increase GABA levels in the rodent frontal cortex, which could lead to elevated \(^3\)H\text{flumazenil} binding. In support of this view, GABA-immunoreactivity is increased in the axosomatic terminals of neurons in layers II, III, V, and VI in the frontal cortex of rats exposed chronically to 0.5 mg/kg/day haloperidol over 4 months [68]. In contrast, a microdialysis study in rats reported a decrease of extracellular levels of GABA in the nucleus accumbens region following chronic haloperidol exposure [61], suggesting a compensatory upregulation of GABA\(\text{AR}\) in our sample of rats.

Studies of bulk tissue GABA levels in the frontal cortex of schizophrenia patients using proton magnetic resonance spectroscopy (\(^1\)H-MRS), however, report either no effect [70,71] or a normalisation of elevated GABA levels [54] following antipsychotic
exposure. The precise nature of the relationship between GABA\textsubscript{A}R binding and GABA levels following antipsychotic exposure therefore remains to be confirmed in future studies using corroborative methods, including microdialysis, \textsuperscript{1}H-MRS and immunohistochemistry to map the cellular localization of these receptor changes. Of particular interest would be further exploration of the subiculum and dCA1 areas of the hippocampus, based on the present findings and on their involvement in the pathophysiology of psychosis [56,61,72].

Limitations of our study should be noted. First, while [\textsuperscript{3}H]Ro15-4513 binds predominantly to diazepam-sensitive GABA\textsubscript{A} sites, it also binds to a diazepam-insensitive site in the cortex and hippocampus with lower affinity [73], which should be taken into consideration when comparing [\textsuperscript{3}H]Ro15-4513’s binding patterns to those of the BZ-sensitive ligand [\textsuperscript{3}H]flumazenil. Second, much of the binding was present within the lower-range of the commercially available standards, which limited the ability to detect a specific signal from regions with lower-binding values (likely reflecting lower receptor density). Hence, we may have underestimated or missed effects of haloperidol in such regions. Third, we only examined the effects of haloperidol; therefore, it is unclear whether the findings reported would generalize to other antipsychotic drugs such as olanzapine, aripiprazole and clozapine. In our previous studies concerning effects of haloperidol and olanzapine on brain volume and cellular markers, we found no clear differences between these compounds [74,75]. Whilst we have no reason to believe that olanzapine for example, would not induce similar effects to haloperidol, this should be explicitly tested in future studies. Future studies should also address sex as a biological variable, since we only used male animals. Finally, it should be taken into consideration that the present data were collected in naïve animals, which do not recapitulate any
features relevant to the pathophysiology of schizophrenia. Hence, haloperidol may act differentially on the GABA system in an initially dysregulated, diseased system. Future studies should therefore investigate the effects of antipsychotics on GABA\(_A\)R in animal models reflective of genetic, environmental or pharmacological risk factors for psychosis.

In summary, our findings indicate that chronic treatment with haloperidol induces dose-specific changes in \(\alpha_1/5\text{GABA}_A\)R in the dCA1 and a generalized increase in BZ-GABA\(_A\)R in healthy rodents. These findings suggest that the mechanisms of action of antipsychotics may also involve the modulation of GABA\(_A\)R in the midbrain-hippocampal loop, predominantly implicating \(\alpha_1-3;5\text{GABA}_A\)R. These mechanisms may be led more specifically by \(\alpha_5\) receptors, particularly in the dCA1 and in a dose-specific manner. The present results align with the notion that administration of antipsychotics can change the responsivity to novel GABA-targeting drugs [76]. Importantly, the ligands used in this study to explore \(\alpha_5\text{GABA}_A\)R (Ro15-4513) as well as BZ-sensitive GABA\(_A\)R (flumazenil) offer promising approaches for translational research as they can be used in cross-species studies including PET in humans [77].

**Funding and disclosure**

This work was partly supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society to GM (#202397/Z/16/Z). ACV acknowledges the financial support of the Medical Research Council (New Investigator Research Grant MR/N025377/1 and Centre Grant MR/N026063/1). ACV discloses receipt of research funding from F. Hoffman La Roche Ltd and UBC Biopharma SPRL as part of a research program on early life immune activation. The views expressed are those of the authors and not necessarily those of F. Hoffman La Roche or UCB Biopharma SPRL. These funders had no influence on the decision to publish this work.
Author contributions

DC, NS, AV and GM designed the experiments. MCC conducted the surgeries and tissue preparation. NS, DC, AK, APY conducted the autoradiography experiments. APY and DC analyzed the data. All authors contributed to writing the manuscript.
REFERENCES

1. McKernan RM, Whiting PJ. Which GABA-receptor subtypes really occur in the brain? Trends in Neurosciences 1996; 19: 139–43.
2. Barnard E., Skolnick P, Olsen RW et al. International Union of Pharmacology . XV . Subtypes of gamma-Aminobutyric Acid A Receptors : Classification on the Basis of Subunit Structure and Receptor Function. 1998; 50: 291–313.
3. Low K, Crestani F, Keist R et al. Molecular and Neuronal Substrate for the Selective Attenuation of Anxiety. Science 2000; 290: 131–5.
4. Mehta AK, Ticku MK. An update on GABA A receptors. Brain Research Reviews 1999; 29: 196–217.
5. Tobler I, Kopp C, Deboer T, Rudolph U. Diazepam-induced changes in sleep : Role of the α1 GABA A receptor subtype. PNAS 2001; 98: 10–5.
6. Sigel E, Steinmann ME. Structure, function, and modulation of GABAA receptors. Journal of Biological Chemistry 2012; 287: 40224–31.
7. Mann EO, Paulsen O. Role of GABAergic inhibition in hippocampal network oscillations. TRENDS in Neurosciences 2007; 30.
8. Whittington MA, Traubtt RD, Jefferys BJGR. Synchronized oscillations in interneuron networks glutamate receptor activation. Letters to Nature 1995; 373: 612–5.
9. Brickley SG, Mody I. Review Extrasynaptic GABA A Receptors : Their Function in the CNS and Implications for Disease. Neuron 2012; 73: 23–34.
10. Benes FM, Berretta S. GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25: 1–27.
11. Benes FM. Amygdalocortical circuitry in schizophrenia: From circuits to molecules. Neuropsychopharmacology 2010; 35: 239–57.
12. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience 2005; 6: 312–24.
13. Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neurosciences 2012; 35: 57–67.
14. Hanada S, Mita T, Nishino N, Tanaka C. [3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sciences 1987; 40.
15. Benes FM, Vincent SL, Marie A, Khan Y. Up-regulation of GABA-A receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 1996; 75: 1021–31.
16. Dean B, Hussain T, Hayes W et al. Changes in Serotonin 2A and GABA A Receptors in Schizophrenia : Studies on the Human Dorsolateral Prefrontal Cortex. Journal of Neurochemistry 1999; 72.
17. Deng C, Huang X. Increased density of GABA A receptors in the superior temporal gyrus in schizophrenia. Exp Brain Res 2006; 168: 587–90.
18. Verdurand M, Fillman SG, Shannon Weickert C, Zavitsanou K. Increases in [3H]Muscimol and [3H]Flumazenil Binding in the Dorsolateral Prefrontal Cortex in Schizophrenia Are Linked to α4 and γ2S mRNA Levels Respectively. PLoS ONE 2013; 8: 11–4.
19. Newell KA, Zavitsanou K, Kum S, Huang X-F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007; 31: 225–33.
20. Glausier JR, Lewis DA. Selective Pyramidal Cell Reduction of GABA A Receptor a 1 Subunit Messenger RNA Expression in Schizophrenia. Neuropsychopharmacology 2011; 36: 2103–10.
21. Beneyto M, Abbott A, Hashimoto T, Lewis DA. Lamina-specific alterations in
cortical GABA receptor subunit expression in schizophrenia. Cerebral Cortex 2011; 21: 999–1011.
22. Volk DW, Pierri JN, Fritschy J, Auh S, Sampson AR, Lewis DA. Reciprocal Alterations in Pre- and Postsynaptic Inhibitory Markers at Chandelier Cell Inputs to Pyramidal Neurons in Schizophrenia. Cerebral Cortex 2002; 12: 1063–70.
23. Impagnatiello F, Guidotti AR, Pesold C et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. 1998; 95: 15718–23.
24. Akbarian S, Kim JJ, Potkin SG, Jennifer O, Bunney WE, Jones EG. Gene Expression for Glutamic Acid Decarboxylase Is Reduced Without Loss of Neurons in Prefrontal Cortex of Schizophrenics. Arch Gen Psychiatry 1995; 52: 258–66.
25. Egerton A, Modinos G, Ferrera D, McGuire P. Neuroimaging studies of GABA in schizophrenia: A systematic review with meta-analysis. Translational Psychiatry 2017; 7: e1147-10.
26. Frankle GW, Cho RY, Prasad KM et al. In Vivo Measurement of GABA Transmission in Healthy Subjects and Schizophrenia Patients. Am J Psychiatry 2015; 172: 1148–59.
27. Lee JS, Lee JD, Park H-J et al. Is the GABA System Related to the Social Competence Improvement Effect of Aripiprazole? An 18 F-Fluoroflumazenil PET Study. Korean Neuropsychiatric Association 2013: 75–80.
28. See R., Toga A., Ellison G. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. Journal of Neural Transmission 1990: 93–109.
29. Dean B, Hussain T, Scarr E, Pavey G, Copolov DL. Extended treatment with typical and atypical antipsychotic drugs Differential effects on the densities of dopamine D2-like and GABA A receptors in rat striatum. Life Sciences 2001; 69: 1257–68.
30. Shirakawa O, Tamminga CA. Basal Ganglia GABA-A and Dopamine D1 Binding Site Correlates of Haloperidol-Induced Oral Dyskinesias in Rat. Experimental Neurology 1994; 127: 1994.
31. Zink M, Schmitt A, May B et al. Differential effects of long-term treatment with clozapine or haloperidol on GABA receptor binding and GAD67 expression. Schizophrenia Research 2004; 66: 151–7.
32. Skilbeck KJ, Reilly JNO, Johnston GAR, Hinton T. The effects of antipsychotic drugs on GABA A receptor binding depend on period of drug treatment and binding site examined. Schizophrenia Research 2007; 90: 76–80.
33. Skilbeck KJ, O’Reilly JN, Johnston GAR, Hinton T. Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA receptor binding sites. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008; 32: 492–8.
34. McLeod MC, Sundram S, Dean B. Treatment with haloperidol and diazepam alters GABA-A receptor density in the rat brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008; 32: 560–7.
35. See RE, Aravagiri M, Ellison GD. Chronic neuroleptic treatment in rats produces persisting changes in GABA-A and dopamine D-2, but not dopamine D-1 receptors. Life Sciences 1989; 44: 229–36.
36. Lian J, Deng C. Early antipsychotic exposure affectd NMDA and GABAA receptor binding in the brains of juvenile rats. Psychiatry Research2019; doi 10.1016/j.psychres.2019.02.001.
37. Kapur S, Vanderspek SS, Brownlee BA, Nobrega JN. Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested
Solution Based on in Vivo Occupancy. Journal of Pharmacology and Experimental Therapeutics 2003; 305: 625–31.
38. Mcleod M, Pralong D, Copolov D, Dean B. The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H] flumazenil and zolpidem. Molecular Brain Research 2002; 104: 203–9.
39. Sancar F, Ericksen SS, Kuchen AM, Teissére JA, Czajkowski C. Structural determinants for high-affinity zolpidem binding to GABA-A receptors. Molecular Pharmacology 2007; 71: 38–46.
40. Lingford-hughes A, Hume SP, Feeney A et al. Imaging the GABA-Benzodiazepine Receptor Subtype Containing the α5-Subunit In Vivo With [11 C] Ro15 4513 Positron Emission Tomography. Journal of Cerebral Blood Flow & Metabolism 2002; 878–89.
41. Maeda J, Suhara T, Kawabe K et al. Visualization of alpha 5 Subunit of GABA A / Benzodiazepine Receptor by [C] Ro15-4513 Using Positron Emission Tomography. Synapse 2003; 47: 200–8.
42. Semyanov A, Walker MC, Kullmann DM, Silver RA. Tonically active GABA A receptors: modulating gain and maintaining the tone. TRENDS in Neurosciences 2004; 27.
43. Caraiscos VB, Elliott EM, You-ten KE et al. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing gamma aminobutyric acid type A receptors. PNAS 2004; 101.
44. Towers SK, Gloveli T, Traub RD et al. α5 subunit-containing GABA A receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro. J Physiol 2004; 3: 721–8.
45. Bonin RP, Martin LJ, Macdonald JF, Orser BA. α5GABA A Receptors Regulate the Intrinsic Excitability of Mouse Hippocampal Pyramidal Neurons. J Neurophysiol 2007; 98: 2244–54.
46. Hauser J, Rudolph U, Keist R, Mohler H, Feldon J, Yee BK. Hippocampal alpha 5 subunit-containing GABA A receptors modulate the expression of prepulse inhibition. Molecular Psychi 2005: 201–7.
47. Gerdjikov T V, Rudolph U, Keist R, Mohler H, Feldon J, Yee BK. Hippocampal a 5 subunit-containing GABA A receptors are involved in the development of the latent inhibition effect. Neurobiology of Learning and Memory 2008; 89: 87–94.
48. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA. A novel α5GABA A a r-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 2011; 36: 1903–11.
49. Donegan JJ, Boley AM, Yamaguchi J, Toney GM, Lodge DJ. Modulation of extrasynaptic GABA-A alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner. Nature communications2019; doi 10.1038/s41467-019-10800-1.
50. Vernon AC, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: A serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biological Psychiatry 2011; 69: 936–44.
51. Myers JFM, Comley RA, Gunn RN. Quantification of [11C]Ro15-4513 GABAα5 specific binding and regional selectivity in humans. Journal of Cerebral Blood Flow and Metabolism 2017; 37: 2137–48.
52. Myers JFM, Rosso L, Watson BJ et al. Characterisation of the contribution of the GABA-benzodiazepine a 1 receptor subtype to [11 C] Ro15-4513 PET images. Journal of Cerebral Blood Flow & Metabolism 2012; 5: 731–44.
53. Sieghart W. Structure and Pharmacology of GABA Receptor Subtypes. Pharmacological reviews 1995; 47: 182–224.

54. de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X et al. Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients. Biological Psychiatry 2017: 1–9.

55. Heckers S, Konradi C. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophrenia Research 2015; 167: 4–11.

56. Lieberman JA, Girgis RR, Brucato G et al. Hippocampal dysfunction in the pathophysiology of schizophrenia : a selective review and hypothesis for early detection and intervention. Molecular Psychiatry 2018: 1764–72.

57. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005; 10: 79–104.

58. Du Y, Grace AA. Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration. Neuropsychopharmacology 2016; 41: 2455–62.

59. Dunn E, Fritschy JM, Carter DB, Merchant KM. Differential distribution of g-aminobutyric acidA receptor subunit (a1, a2, a3, a5 and b2+3) immunoreactivity in the medial prefrontal cortex of the rat. Neuroscience Letters 1996; 210: 213–7.

60. Verhoeven KJF, Simonsen KL, Mcintyre LM. Implementing false discovery rate control : increasing your power. OIKOS 2005: 643–7.

61. Lisman JE, Grace AA, Street S. The Hippocampal-VTA Loop : Controlling the Entry of Information into Long-Term Memory. Neuron 2005; 46: 703–13.

62. Miller LG, Greenblatt DJ, Barnhill JG, Summer WR, Shader RI. “GABA shift” in vivo : enhancement of benzodiazepine binding in vivo by modulation of endogenous GABA. European Journal of Pharmacology 1988; 148: 123–30.

63. Tallman JF, Thomas JW, Gallager DW. GABAergic modulation of benzodiazepine binding site sensitivity. Nature 1978; 274: 383–5.

64. Frankle WG, Cho RY, Narendran R et al. Tiagabine Increases [11C]flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects. Neuropsychopharmacology 2009: 624–33.

65. Stokes PRA, Myers JF, Kalk NJ et al. Acute increases in synaptic GABA detectable in the living human brain: A [11C]Ro15-4513 PET study. NeuroImage 2014; 99: 158–65.

66. Turrone P, Remington G. The vacuous chewing movement ( VCM ) model of tardive dyskinesia revisited: is there a relationship to dopamine D 2 receptor occupancy ? 2002; 26.

67. Xu T-X, Yao W-D. D1 and D2 dopamine receptors in separate circuits cooperate to drive associative long-term potentiation in the prefrontal cortex. Proceedings of the National Academy of Sciences 2010; 107: 16366–71.

68. Vincent SL, Adamec E, Sorensen I, Benes FM. The Effects of Chronic Haloperidol Administration on GABA-Immunoreactive Axon Terminals in Rat Medial Prefrontal Cortex. Synapse 1994; 35: 26–35.

69. See RE, Chapman MA, Klitenick MA. Chronic neuroleptic administration decreases extracellular GABA in the nucleus accumbens but not in the caudate-putamen of rats. Brain Research 1992; 588: 177–80.

70. Tayoshi S, Nakataki M, Sumitani S et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: A proton magnetic resonance spectroscopy study. Schizophrenia Research 2010; 117: 83–91.

71. Bojesen KB, Ebdrup BH, Jessen K et al. Treatment response after 6 and 26 weeks is
related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis. Psychological Medicine 2019.

72. Floresco SB, Todd CL, Grace A a. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience 2001; 21: 4915–22.

73. Turner DM, Sapp DW, Olsen RW. The Benzodiazepine/Alcohol Antagonist Ro15-4513: Binding to a GABA-A Receptor Subtype That is Insensitive to Diazepam. The Journal of Pharmacology and Experimental Therapeutics 1991; 257: 1236–42.

74. Vernon AC, Crum WR, Lerch JP et al. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs - Linking magnetic resonance imaging findings to cellular pathology. Biological Psychiatry 2014; 75: 982–90.

75. Cotel MC, Lenartowicz EM, Natesan S et al. Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology 2015; 25: 2098–107.

76. Gill KM, Cook JM, Poe MM, Grace AA. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophrenia Bulletin 2014; 40: 341–50.

77. Horder J, Andersson M, Mendez MA et al. GABA A receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science Translational Medicine 2018; 10: eaam8434.